Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) in HER2+ Advanced Breast Cancer and Other Solid Tumors
Conditions: HER2+ Advanced Breast Cancer; Other Solid Tumors Interventions: Drug: ADCC-R-Epo-R T-cells + Trastuzumab; Drug: Erythropoietin beta; Drug: Fludarabine and Cyclophosphosphamide Sponsor: National University Hospital, Singapore Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Hospitals | Research | Singapore Health | Study